申请人:Delta Pharmaceuticals, Inc.
公开号:US05658908A1
公开(公告)日:1997-08-19
Diarylmethylpiperazine compounds having utility as receptor-binding species, e.g., for mediating analgesia, and for combatting drug addiction, alcohol addiction, and drug overdose. The compounds may be administered orally, rectally, topically, nasally, ophthalmically, or parenterally (subcutaneously, intramuscularly, and intravenously), for veterinary and human use, and include delta receptor and mu receptor binding species.
二芳基甲基哌嗪化合物具有作为受体结合物种的效用,例如用于介导镇痛,以及用于对抗药物成瘾,酒精成瘾和药物过量。这些化合物可以经口、直肠、局部、鼻腔、眼部或经肌肉注射、皮下注射和静脉注射等方式进行兽医和人类使用,并包括δ受体和μ受体结合物种。